From our Industry Experts

TMCNet:  Research and Markets: Osteoporosis - Pipeline Review, H1 2014: 60 Companies and 94 Drugs Profiled

[May 07, 2014]

Research and Markets: Osteoporosis - Pipeline Review, H1 2014: 60 Companies and 94 Drugs Profiled

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Osteoporosis - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sitesand industry-specific third party sources.

Companies Involved:

  • Affectis Pharmaceuticals AG
  • Alethia Biotherapeutics Inc.
  • Alkem Laboratories Ltd.
  • Amgen Astellas BioPharma K.K.
  • Amgen Inc.
  • Amura Holdings Ltd.
  • Asahi Kasei Pharma Corp.
  • Astellas Pharma Inc.
  • Ausio Pharmaceuticals, LLC
  • Azelon Pharmaceuticals Inc.
  • B&C Biopharm
  • Biodel Inc.
  • Biolo ElexoPharm GmbH
  • Bone Medical Limited
  • Bone Therapeutics SA
  • Calzada Limited
  • CardioVascular BioTherapeutics, Inc.
  • Centre de Regulacio Genomica
  • Chugai Pharmaceutical Co., Ltd.
  • Shenogen Pharma Group Ltd.
  • Siena Biotech S.p.A.
  • TSRL, Inc.
  • Takeda Pharmaceutical Company Limited
  • Uni-Bio Science Group Ltd.
  • Ventria Bioscience
  • Wroclawskie Centrum Badan EIT+ Sp. z o.o.
  • Zealand Pharma A/S
  • Zosano Pharma, Inc.
  • Zydus Cadila Healthcare Limited

Drug Profiles:

  • bazedoxifene acetate
  • denosumab
  • romosozumab
  • odanacatib
  • BA-058
  • zoledronic acid
  • ibandronate sodium
  • estrone sodium sulfate + (levonorgestrel + Ethinyl Estradiol) + prasterone
  • teriparatide
  • COVOP-77
  • E-4
  • teriparatide
  • calcitonin
  • PHN-031
  • teriparatide
  • teriparatide ZP Patch
  • alendronate sodium
  • DP-001
  • blosozumab
  • ES-1
  • AUS-131
  • IMD-2560
  • MIV-711
  • DW-1350
  • ZYPH-0907
  • OCT-1547
  • teriparatide
  • CDRI-99/373
  • VEN-130

For more information visit

[ Back To Real Time Communications's Homepage ]


  Subscribe here for RTCW eNews   Upcoming Webinars

Featured Videos

Kandy Wrapper: Visual Attendant
Kandy Visual Attendant is ready for resale. The turnkey solution can be custom branded ...

NFV Made Easy
Moving to an NFV gives you An agile and lower cost network. With GENBAND's NFV Solutions ...
Kandy Bus 2016 Connected Experience
Kandy presents A Connected Experience, a three-part fire-starter where we build entire Kandy-enabled ...

View All